SCYNEXIS ($SCYX) Stock Hub: BARDA Backs SCY-247 as ADPKD Advances

04 Catalyst map: what happens next and why

The dates below distinguish management guidance from fixed events. The September 28 award is already an accomplished event; future work under that award is the catalyst. Impact levels are Merlintrader’s qualitative assessment of how much a development could change the investment thesis, not a forecast of the share-price move.

No confirmed PDUFA date has been identified for SCY-770 or SCY-247. FDA designations facilitate development; they do not create an approval deadline. Registry completion estimates are not company-announced readout dates. The first decisive ADPKD question remains whether an effect observed in patients can be distinguished from noise and translated into a clinically meaningful benefit. SEC Q2 guidance · September 28 update

05 SCYNEXIS: two development paths with different economics

SCYNEXIS is rebuilding its investment case around severe rare diseases. The acquisition of Poxel’s direct AMPK activator program in March 2026 brought in PXL770, now SCY-770, and made autosomal dominant polycystic kidney disease, or ADPKD, the lead development opportunity. The September 28, 2026 BARDA award adds a second development driver by supporting SCY-247. Kidney disease remains the lead program, while the antifungal portfolio gains a more concrete financing route.

The portfolio now has three distinct economic roles. SCY-770 requires the company to establish clinical benefit in ADPKD. SCY-247 is a wholly owned antifungal candidate whose oral and intravenous formulations could support a hospital treatment strategy. BREXAFEMME is an approved product licensed to GSK, with potential future royalties and sales milestones dependent on the partner’s commercial execution. These assets should not be counted as three equivalent, revenue-producing businesses.

The strategic attraction is diversification across different mechanisms and markets. The corresponding challenge is execution: a small organization must allocate clinical, manufacturing and financial resources between programs with different development requirements. A successful dose-selection study can move a program forward without answering whether it works in patients. A partner’s relaunch can create income without demonstrating the value of the company’s remaining pipeline. Keeping these distinctions visible prevents progress in one program from being mistaken for validation of the entire company.

Sources: SCYNEXIS Q2 2026 Form 10-Q; official strategic collaborations; September 28 BARDA award.

06 SCY-770: testing AMPK activation in ADPKD

ADPKD is an inherited disorder in which fluid-filled cysts progressively enlarge the kidneys and can impair their function. The clinical objective is to slow that progression before patients reach kidney failure. A drug that changes a laboratory measurement without producing a meaningful effect on disease progression would address only part of that objective.

SCY-770 is an oral small molecule that directly activates AMP-activated protein kinase, or AMPK, an important regulator of cellular energy handling. The development hypothesis is that this mechanism can influence several processes involved in cyst growth, including abnormal metabolism, cell proliferation and inflammatory signaling. Preclinical findings support testing the approach, but they do not establish a treatment effect in people with ADPKD.

Two measurements help explain the program. Height-adjusted total kidney volume, abbreviated htTKV, uses imaging to follow kidney enlargement while accounting for body size. Estimated glomerular filtration rate, or eGFR, measures kidney function. They answer related but different questions. An early imaging signal could make the biological hypothesis more credible; durable preservation of function would provide a more direct indication of clinical benefit. Neither should be substituted for the other when interpreting a trial.

The commercial possibility is an additional disease-modifying option with a different mechanism from established therapy. That possibility depends on finding an exposure that patients can tolerate over time and then showing a reproducible effect. Oral administration is convenient, but convenience alone does not establish competitiveness. Likewise, experience with the same molecule in another disease provides useful safety information without proving that the dose, population or duration appropriate for ADPKD has already been established.

Sources: SCYNEXIS SCY-770 scientific overview; March 31, 2026 investor presentation.

07 SCY-770 clinical evidence: what is established and what comes next

The previous clinical experience with PXL770 is useful but requires a clear boundary. In the published STAMP-NAFLD Phase 2a trial, 120 participants received one of three oral dosing regimens or placebo for 12 weeks. The study did not meet its primary endpoint of liver-fat improvement versus placebo. Diarrhea occurred in 17%–23% of active-treatment participants and in none receiving placebo; the publication reported no life-threatening events or treatment-related deaths. Metabolic signals generated further hypotheses, but neither those signals nor the overall tolerability findings demonstrate efficacy in ADPKD.

The current Phase 1 program addresses a practical prerequisite: how food and repeated dosing affect exposure. Its two Australian registry entries describe healthy volunteers, rather than a kidney-disease efficacy population. Safety and tolerability are primary assessments, alongside pharmacokinetic work that is intended to inform the next study.

The food-effect record was last updated on June 25, 2026. The repeated-dose record was updated on August 28 and reported eight participants accrued toward the target of sixteen. Both records showed recruiting status. These are dated registry observations: an anticipated completion date is not confirmation that data collection finished, and an older recruiting label does not by itself establish the study’s present operational status.

The planned ADPKD Phase 2 design shown in the March presentation included 50 participants: twenty in each of two active-dose groups and ten receiving placebo. A 16-week blinded period would be followed by 32 weeks of open-label treatment. Planned assessments included htTKV, eGFR and additional renal or biological measurements. The proposed population comprised adults aged 18–55 with rapidly progressing imaging categories, eGFR of 45–90 and no tolvaptan use. This remains a company-described plan; it should not be presented as a finalized registry protocol.

On August 10, management retained a Q3 2026 Phase 1 topline window, Q4 2026 Phase 2 initiation and an early efficacy readout in the second half of 2027. Those are development expectations, not guaranteed event dates. A favorable Phase 1 result would principally support dose selection. The subsequent patient study must address the more demanding question of whether the proposed mechanism produces an effect large and consistent enough to justify further development.

Sources: published STAMP-NAFLD results; food-effect registry; repeated-dose registry; planned Phase 2 design, slide 13; August 10, 2026 update.

08 SCY-247: BARDA support strengthens the route into patient trials

SCY-247 is SCYNEXIS’s second-generation fungerp, a triterpenoid antifungal targeting glucan synthesis. The program aims to address severe invasive fungal infections, including infections involving difficult-to-treat organisms. Laboratory and animal findings provide the rationale for development; they do not establish that the candidate will overcome resistance or improve outcomes in the clinical populations ultimately studied.

The oral Phase 1 SAD/MAD results announced on September 30, 2025 included 66 healthy participants receiving SCY-247 and 22 receiving placebo. No serious or severe treatment-emergent adverse events were reported. Headache occurred in 16.7% versus 4.5%, while diarrhea was reported in 9% of each group. One participant stopped because of an adverse event considered unrelated to treatment. The 200 mg and 300 mg once-daily regimens reached or exceeded a preliminary exposure target derived from preclinical invasive-candidiasis models.

That exposure result is a bridge between preclinical work and patient trials, rather than evidence that infections were successfully treated. Healthy-volunteer studies cannot fully anticipate tolerability in severely ill patients, who may have organ dysfunction, multiple medications and a substantially different risk profile.

The company announced first dosing in the intravenous Phase 1 study on February 26, 2026. The September 28 announcement confirms completed dosing with analysis ongoing. The earlier Q3 topline window has not yet become a disclosed result. An intravenous option could support initial hospital treatment, while an oral option could offer flexibility later in the treatment course. Demonstrating useful exposure with both formulations is therefore relevant to the intended product profile.

BARDA’s initial contract period provides approximately $18.5 million to support oral and IV SCY-247 advancement into Phase 2. The maximum potential support is approximately $214 million over a period that may extend to ten years, conditional on all options being exercised. The scope could extend through NDA submissions for invasive-candidiasis treatment and prevention of invasive fungal infections in high-risk patients. It is a cost-sharing arrangement, not an upfront $214 million cash receipt.

The August filing anticipated a possible Phase 2 start in the first half of 2027. The award materially addresses the financing question but supplies no replacement start date. SCYNEXIS retains its share of program costs, and clinical execution remains necessary. Management says SCY-770 plans and cash runway into 2029 are unchanged.

Sources: SCY-247 scientific overview; oral Phase 1 results; IV study initiation; Q2 Form 10-Q: updated Phase 2 timing; BARDA contract announcement.

09 BREXAFEMME and GSK: commercial optionality after MARIO

BREXAFEMME, or ibrexafungerp, remains a different proposition from the investigational pipeline. Its approved US indications are treatment of vulvovaginal candidiasis and reduction in the incidence of recurrent vulvovaginal candidiasis. The July 2026 FDA label identifies GSK and retains a boxed warning for embryo-fetal toxicity, including a contraindication in pregnancy. Regulatory approval and an updated label do not, by themselves, demonstrate that a commercial relaunch has occurred.

The manufacturing disruption originated in a potential cross-contamination risk involving a non-antibacterial beta-lactam drug substance. The FDA’s September 2023 notice concerned two recalled lots; it did not describe bacterial contamination. The clinical hold was subsequently lifted in April 2025. Nevertheless, the later agreement with GSK ended the MARIO development effort. The NDA transfer to GSK was completed in November 2025, leaving the partner central to any commercial restart.

MARIO’s registry now records termination for a strategic decision, described by the sponsor as unrelated to safety or efficacy concerns. Only 68 participants were enrolled against a target of 220. Results posted on August 10, 2026 report day-30 deaths of four among 36 participants assigned to ibrexafungerp step-down therapy and three among 32 assigned to the comparator strategy, with five outcomes unknown. The independent review needed for the global-response endpoint was canceled. Missing endpoint data must not be interpreted as zero responses, and the truncated study cannot establish a reliable comparative conclusion.

FURI and CARES are also historical, completed studies. FURI enrolled 233 participants with varied refractory or treatment-intolerant fungal diseases; the registry reports 142 global-response successes, 69 failures and 22 non-evaluable outcomes. CARES enrolled thirty people with Candida auris infection and reported twenty-one global successes. Both lacked a randomized comparator. The registries also report deaths in these seriously ill populations, which cannot automatically be attributed to treatment or used to make uncontrolled comparisons. Their findings concern ibrexafungerp, not SCY-247.

The economic opportunity therefore depends on execution outside SCYNEXIS’s direct commercial control. The NDA-transfer announcement described potential sales milestones of up to $145.5 million and low-to-mid-single-digit royalties net of payments to Merck. These are contingent future receipts. They should not be treated as existing cash, a guaranteed revenue stream or evidence that the abandoned MARIO indication will return.

Sources: FDA label, July 2026; FDA recall notice; 2025 Form 10-K; MARIO; FURI; CARES; NDA transfer and commercial economics.

10 Competition and the regulatory evidence still required

SCY-770 would enter a field with an established treatment and several development approaches. Tolvaptan, marketed as JYNARQUE, is approved to slow kidney-function decline in adults at risk of rapidly progressing ADPKD. Its liver-injury risk, required monitoring and restricted distribution create treatment burdens, but do not negate its demonstrated clinical role. A new candidate must earn differentiation through efficacy, tolerability and practical usability.

Vertex reported completed enrollment in its AGLOW Phase 2 study of VX-407 in August 2026. That 26-person, single-arm, 52-week study targets a subset of PKD1 variants and assesses htTKV. Novartis presented a proposed global Phase 3 design for farabursen, an anti-miR-17 oligonucleotide, at ERA 2026. A study-design presentation alone does not confirm operational initiation. Differences in populations, mechanisms, duration and controls prevent direct comparisons of headline imaging changes.

SCY-247 faces a separate competitive setting that includes established azoles and echinocandins. Rezafungin, marketed as REZZAYO, already provides a once-weekly intravenous option for candidemia and invasive candidiasis in patients with limited alternatives. SCY-247’s oral/IV ambition could be useful, but it must demonstrate clinical benefit and an acceptable safety profile rather than rely on laboratory activity alone.

Regulatory designations can facilitate development without settling these questions. SCY-770’s Orphan Drug status is not approval, and the company explicitly states that no FDA agreement has been reached on its proposed imaging-based accelerated pathway. SCY-247’s QIDP, Fast Track and Orphan designations likewise do not remove the requirement for adequate evidence. There is no confirmed PDUFA date for either candidate. The relevant sequence remains dose selection, patient efficacy, a suitable confirmatory program and an agreed regulatory submission strategy.

Sources: JYNARQUE FDA label; Vertex Q2 2026 update; Novartis ERA 2026 announcement; FDA REZZAYO evidence summary; SCYNEXIS regulatory and development disclosures.

11 Financial performance: cash generation and accounting earnings

SCYNEXIS’s financial statements describe a development company with irregular licensing income, rather than an established stream of commercial product sales. The $20.601 million of 2025 revenue included $19.157 million of licensing revenue and a $1.444 million adjustment to historical product revenue associated with the BREXAFEMME recall. A $17.2 million licensing catch-up followed the amended GSK agreement. These items make the annual revenue figure a poor starting point for extrapolating recurring sales.

*Q2 operating cash flow is a Merlintrader calculation: the six-month outflow less the first-quarter outflow. Individual periods retain the amounts reported in their respective filings; rounding can produce differences of $0.001 million between quarterly sums and cumulative figures. Sources: 2025 Form 10-K, Q1 Form 10-Q and Q2 Form 10-Q.

The positive Q2 net result requires particular care. A $14.152 million noncash gain from remeasuring warrant liabilities outweighed a $7.775 million operating loss. Falling warrant valuations can improve reported earnings without generating money for clinical development. The result therefore does not establish operating profitability, and the first-half net loss remains $13.902 million.

The SCY-770 acquisition creates a second timing difference. Its $8 million upfront cost entered Q1 research and development expense, but the payment occurred in April. It consequently increased Q2 operating cash outflow. Excluding only that payment produces $6.885 million of Q2 outflow, a Merlintrader calculation rather than a company-reported adjusted measure or a forecast. Finally, the $24.8 million received from GSK helped reduce the 2025 operating outflow. Comparing the unusually low annual burn with a development quarter without explaining that receipt would conceal the financing demands of the business. FY2025 results; Q2 results.

12 Cash, balance-sheet resilience and runway

At June 30, 2026, SCYNEXIS reported $71.130 million of cash, cash equivalents and investments. That total comprises $10.487 million of cash and equivalents, $43.596 million of short-term investments and $17.047 million of longer-term investments. Restricted cash of $0.189 million is separate. This distinction matters: the $71.1 million headline measures the combined financial resource pool, not money held entirely in bank accounts.

The comparable totals were $56.278 million at December 31, 2025 and $72.416 million at March 31, 2026. The March balance already included approximately $24 million of the $40 million private placement, with the remaining approximately $16 million received on April 1. Adding the entire financing to either reported quarter-end balance would double-count proceeds. Q1 balance sheet and financing note; Q2 balance sheet.

The latest management update, September 28, explicitly retains guidance that resources should fund operations into 2029. The May update had specified mid-2029; the newer wording does not identify a quarter or month. Runway is a forward-looking operating-plan estimate, sensitive to trial costs, timing and development choices. Dividing cash by a single historical quarter would not reproduce that plan, especially when acquisitions and exceptional receipts distort the denominator. September 28 runway confirmation.

The June balance sheet contains no conventional financial borrowing following repayment of the remaining $14 million convertible notes in March 2025. It nevertheless includes $8.040 million of total liabilities, including $1.945 million of operating lease obligations and $0.796 million of warrant liabilities. Shareholders’ equity was $66.930 million. The practical question is whether spending stays aligned with the funded clinical programme; a long stated runway improves flexibility but does not finance every possible future pivotal programme or eliminate the option of raising equity.

13 Capital structure, warrants and the financing clock

The latest verified cover-page count is 9,949,609 common shares outstanding on August 1, 2026, identical to the June 30 balance-sheet count. All figures below use the basis following the one-for-eight reverse split effective May 29. The comparative December 2025 count in the Q2 filing is 5,442,688; the increase to June is 82.81%, a Merlintrader calculation. Earlier filings and the May resale prospectus contain much larger pre-split counts, which cannot be combined directly with today’s basis.

Source: Q2 Form 10-Q, Notes 7, 8 and 12. Instruments are not all immediately exercisable, and this table does not predict issuance.

The pre-funded total is 1,892,471. Adding it to issued common gives 11,842,080, a Merlintrader calculation showing a broader economic share base; it is not the legally outstanding common count. Separately, the filing’s 11,862,597 shares reserved for future issuance include unallocated equity-plan capacity. That figure must not be labelled outstanding warrants or treated as immediate, certain dilution.

The March financing closed April 1 with $40.0 million gross and $36.9 million final net proceeds. Common shares and accompanying warrants were sold for a combined $7.36 per unit on the adjusted basis. Full cash exercise of the common warrants could produce another $52.2 million, but that is conditional funding. The warrants became exercisable after shareholder approval on June 25. They expire at 5 p.m. New York time on the earlier of April 1, 2031 and the thirtieth day after public release of Week 48 topline results from the SCY-770 ADPKD Phase 2 proof-of-concept trial. An earlier efficacy update is not automatically that contractual event.

The $50 million nominal Cantor ATM remains another financing channel mentioned in the Q2 filing; no ATM shares were sold through December 2025. That nominal ceiling is not a verified September amount immediately available under applicable issuance limits. The May 8 resale prospectus registers PIPE holders’ resale securities, with no company proceeds from resale itself. Nasdaq confirmed minimum-bid compliance on June 15 following the reverse split. Restored listing compliance resolves that historical notice; it does not remove dilution or clinical execution risk.

14 BARDA, partnership economics and contingent obligations

The September 28 BARDA award changes SCY-247’s funding position. Its initial base period provides approximately $18.5 million to support oral and intravenous development into Phase 2 invasive candidiasis. The approximately $214 million maximum requires exercise of all options, potentially over ten years. This is a cost-share arrangement covering eligible direct and general and administrative costs; SCYNEXIS expects to fund its near-term contribution within its existing plan. The award therefore adds a programme funding source, not $214 million of unrestricted cash, and management explicitly leaves runway into 2029 unchanged. September 28 BARDA announcement.

GSK offers a separate potential income stream. The October 2025 resolution produced $24.8 million of non-refundable payments and accompanied the wind-down of Phase 3 MARIO. No additional development milestones specifically associated with MARIO remain payable. BREXAFEMME’s NDA transferred to GSK in November 2025. The current opportunity is approximately $146 million of conditional milestones tied to annual net-sales thresholds, plus net royalties in the low-to-mid single digits after Merck payments. The more precise milestone total is $145.5 million: these are cumulative milestone opportunities, not $146 million payable every year. Relaunch timing and demand remain uncertain. GSK agreement in the annual report; FY2025 economics; Q2 partner update.

SCY-770 introduces obligations in the opposite direction. The Poxel acquisition required $8 million upfront, paid in April, and allows up to $8 million of additional development milestones, including $2 million upon initiation of the first Phase 2 trial. Commercial milestones can reach $180 million, with $125 million triggered at annual sales of at least $1 billion. This aligns part of the price with progress, while the planned Phase 2 start has a near-term cash consequence. The large sales-linked maximum is contingent consideration, not an overdue liability. BARDA funding is specific to SCY-247 and should not be assumed to cover these SCY-770 payments. Q2 acquisition note.

15 Management, governance and insider transactions

David Angulo remains President and Chief Executive Officer as the company broadens from antifungal development into rare kidney disease. September appointments give this transition a concrete organisational dimension. The relevant test for investors is whether the new team delivers trial execution, capital discipline and interpretable data; impressive biographies alone cannot establish those outcomes.

Sanjay Subramanian became CFO on September 9, 2026, with the appointment announced September 10. Ivor Macleod ceased serving as CFO on September 9 and remains with the company through October 9 to support the handover. Subramanian previously served as CFO and Head of Business Development at Inozyme and was involved in its acquisition by BioMarin. That experience is relevant to financing and transaction execution, but is not evidence that a SCYNEXIS sale is planned. September CFO Form 8-K.

Todd Minga joined as Senior Vice President, Research & Development, effective September 14. His background includes nephrology practice and development roles at Akebia, Maze and IQVIA. Steven K. Burke joined the board effective September 18, announced September 22, bringing kidney-disease drug-development experience from Akebia. These additions are consistent with SCY-770’s strategic importance; their clinical expertise does not substitute for controlled evidence of efficacy in ADPKD. Minga appointment; Burke appointment.

Insider filings require careful classification. Subramanian received 100,000 options at a $4.91 strike on September 9. Burke received 5,750 RSUs and 5,750 options at a $4.46 strike on September 18. Their Form 4 transaction code is A: these are compensation grants, not open-market purchases. In contrast, Angulo participated in the March placement with 13,586 common shares and accompanying warrants, roughly $100,000 at the combined adjusted unit price. That is a funded investment in the placement, still distinct from a discretionary exchange purchase. Subramanian Form 4; Burke Form 4; PIPE participation.

16 Ownership, filing limitations and analyst coverage

Institutional involvement is visible in the financing and ownership filings, but the reported percentages do not share a clean, uniform denominator. Beneficial ownership can include warrant shares a holder may acquire, and contractual exercise caps limit how many instruments count at one time. Adding these percentages would not produce a reliable institutional ownership total or a free-float estimate.

Sources: CVI/Heights Schedule 13G/A, Adage Schedule 13G, Great Point Schedule 13G/A. These are selected disclosed positions, not a complete ownership census. Managers and individual co-filers are not additional separate holdings.

Great Point illustrates why the footnotes matter. Its detail identifies 944,292 common shares and 3,131,776 underlying warrant shares, but only 53,047 warrant shares exercisable within the stated 9.99% cap. The cover aggregate of 4,076,068 combines the broader quantities while reporting the capped percentage. This internal inconsistency belongs to the filing: treating all 4.076 million as issued common held by the manager would misstate the share structure. It also prevents using that figure in an ownership pie chart without an unsupported assumption.

The company’s official coverage roster lists Brookline Capital Markets/Kemp Dolliver, Guggenheim Partners/Vamil Divan, H.C. Wainwright and Maxim Group/Jason McCarthy. This establishes named coverage, not a current consensus valuation. No original dated analyst report with a verifiable price target was obtained for this review. Accordingly, no numerical target is reproduced. Historical targets require particular caution after a reverse split: a change in per-share units is not a change in enterprise value, and a mechanically adjusted target is not a new analyst opinion. Official analyst coverage.

17 Market structure and retail sentiment

The issued common share count is modest, but a small share count is not automatically a small economic float. Pre-funded warrants, registered resales, beneficial-ownership caps and future exercises complicate the picture. Any valuation needs to identify whether it uses issued common only or a broader economic share base, and it must avoid mixing pre-split and post-split data. A dated market capitalization is not a measure of the amount BARDA has committed to pay.

Finviz’s public snapshot observed on September 28 displayed a market capitalization of $46.27M alongside 9.95M rounded shares outstanding. This is the provider’s dated market figure, not a new SEC share count. Its short-interest field was approximately 0.46M shares, 4.81% of its reported 9.56M float; the snapshot did not expose the settlement date. These lagged fields cannot establish current short positioning. No aggregate institutional-ownership percentage is inferred from the selected SEC ownership filings.

Stocktwits snapshot · September 28, 2026, around 14:07 CEST

The Stocktwits snapshot reported 10,036 watchers, a normalized sentiment score of 78/100 labeled extremely bullish, and a current message-volume score of 58/100 labeled high. Its displayed split was 100% bullish / 0% bearish. These are different provider measures: the percentage split is not the same calculation as the normalized score. Neither measures the entire shareholder base.

The recent messages sampled contained momentum language and repeated price-level references. They came from trader and retail-user accounts, not institutional research analysts. The sample was small and included repeated participants, so it is not used to estimate broad investor conviction. The useful question is whether discussion focuses on the $18.5M base and cost-sharing terms or only on the $214M headline ceiling. A narrative that ignores conditional funding can run ahead of the underlying evidence.

Stocktwits SCYX snapshot and discussion · Finviz structural snapshot, observed September 28 · SEC capital structure

18 Risk map and red flags

Clinical risk: an acceptable healthy-volunteer safety profile does not establish efficacy or long-term tolerability in people with renal disease or invasive infection. SCY-770’s renal hypothesis, SCY-247’s efficacy and the transition from exposure targets to patient outcomes each require evidence. Small early studies can miss uncommon adverse events and overstate apparent effect sizes.

Financing and contract risk: the BARDA award is a cost-share arrangement. Option exercises and eligible costs matter, and the company still bears part of development expenditure. The $214M maximum cannot be added to cash or equity value. Existing pre-funded warrants, common warrants, stock-based awards and the ATM framework mean that non-dilutive program support does not eliminate corporate dilution risk.

Execution and concentration: a lean organization advancing two programs must manage clinical operations, manufacturing, data quality and regulatory work. The new nephrology hires are relevant capabilities, but appointments do not prove execution. Delays can consume time and cash even when they do not imply clinical failure.

Partner and commercial risk: GSK controls the BREXAFEMME relaunch. NDA transfer and an updated label are distinct from confirmed market availability, sales uptake or royalty receipts. Contingent milestone maxima should never be treated as an ordinary recurring revenue forecast.

Market and reporting risk: microcap liquidity can change abruptly around a headline. Historic accounting gains, split-adjusted ownership data and overlapping co-filers can make quick comparisons misleading. The Q2 profit was not an operating profit; an insider award was not an open-market purchase; a beneficial holding may include warrants. Those distinctions materially change the interpretation. SEC risk factors and notes · BARDA conditions

19 Monitoring checklist and evidence that would change the thesis

The most useful next update is not a higher headline contract value. It is evidence that converts a conditional development plan into completed work. For SCY-247, inspect the IV dataset, infusion tolerability, exposure, dose schedule and Phase 2 protocol; track actual BARDA option exercises and the company’s share of costs. For SCY-770, inspect food-effect results, dose rationale, trial enrollment criteria and the relationship between imaging changes and renal-function measures.

At each financial reporting date, reconcile unrestricted liquidity, operating cash flow and acquisition or milestone payments. Separate reimbursements from unrestricted cash receipts and look for a revised runway statement. Recalculate the share base only from company filings, distinguishing common, pre-funded, ordinary warrants, options, RSUs and unallocated plan reserves. A new S-3 for resale need not represent new cash raised by the issuer.

Watch for an actual GSK launch announcement and product revenue before assuming that commercial economics have begun. Check whether the company changes the Phase 2 start windows or the intended early ADPKD readout. If a quarter ends without a release, label the earlier guidance as elapsed and seek an update; do not silently move the date forward. SCYNEXIS news archive · Latest quarterly filing · BARDA development plan

20 Research conclusion

SCYNEXIS combines a newly prioritized ADPKD program with an antifungal asset that has obtained meaningful external development support. BARDA makes the SCY-247 financing pathway more concrete; it does not turn a Phase 1 asset into an approved therapy. SCY-770 remains the lead program, with patient-level renal evidence still ahead. BREXAFEMME adds partner-dependent optionality, not assured near-term cash generation.

The balance sheet provides room to work under management’s current plan, while the capital structure demands attention to per-share economics. The central analytical task is to follow three separate ledgers: clinical evidence, cash actually available and shares or equivalent claims outstanding. Progress in one does not automatically settle the other two. September 28 company update · SEC Q2 financial and operating context